XenoTherapeutics
XenoTherapeutics Foundation is a Massachusetts not-for-profit research foundation developing clinical-stage regenerative medicine products from genetically engineered pigs. Its lead therapy, realSKIN, is a living skin transplant with FDA RMAT designation for severe injuries.
- Company typePrivate
- Founded2016
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What XenoTherapeutics does
XenoTherapeutics Foundation is a Massachusetts-based, not-for-profit biotechnology research foundation founded in 2016 and headquartered in the Greater Boston Area (Massachusetts and New Hampshire). The foundation operates a clinical-stage xenotransplantation platform that uses genetically engineered pigs as a consistent, living donor source to produce regenerative medicine products described as "nearly human," positioning the platform as a scalable alternative to donated human cadaver tissue. Its lead product is realSKIN, a living skin transplant designed to support healing after severe injuries such as burns and large wounds; realSKIN has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, and the foundation is exploring additional indications through partnerships with academic institutions and investigators. The registered trademark "realSKIN" anchors the commercial brand, and the platform is intended to extend to a broader range of cell, tissue, and organ applications over time.
Commercially, XenoTherapeutics operates as a research foundation rather than a traditional revenue-generating biopharma, with 1–10 employees, no publicly disclosed revenue, no disclosed pricing, and no disclosed funding rounds with material dollar amounts. Therapy commercialization is described as a one-time license model, and the foundation distributes realSKIN through regional clinical partnerships with healthcare providers, hospitals, and burn centers, alongside academic collaborations for indication expansion and expanded access programs. Strategic activity in 2025–2026 has been dominated by acquisitions rather than organic launches: the foundation completed the acquisition of ESSA Pharma Inc. (a prostate cancer pharmaceutical company) in October 2025 for approximately US$6.7 million and the acquisition of Repare Therapeutics Inc. (a clinical-stage oncology precision medicine company) in January 2026 for approximately $78.2 million, consolidating these entities under wholly owned subsidiaries including a dedicated acquisition vehicle, Xeno Acquisition Corp.
The customer base is a horizontal patient segment — individuals with severe injuries, burns, and wounds who today depend on limited cadaver tissue — served through clinical channels rather than direct consumer engagement. Leadership consists of CEO Jon W. Adkins and CFO Krysta Moulton, both listed as co-founders. The overall posture is that of a research-oriented foundation using its xenotransplantation platform and acquired biotech assets to advance regenerative medicine while pursuing broader oncology exposure via M&A.
XenoTherapeutics firmographics
Firmographics- Name
- XenoTherapeutics
- Legal name
- XenoTherapeutics Foundation
- Website
- https://xenotherapeutics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- XenoTherapeutics Foundation is a Massachusetts not-for-profit research foundation developing clinical-stage regenerative medicine products from genetically engineered pigs. Its lead therapy, realSKIN, is a living skin transplant with FDA RMAT designation for severe injuries.
- Ownership category
- akta.pro rank
XenoTherapeutics industry classification
Industry- Product category
- Regenerative Medicine / Xenotransplantation Therapies
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industries
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Tissue Engineering & Biomaterial Scaffolds (HLAMANAC)
Keywords
Where XenoTherapeutics is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
XenoTherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales
Revenue model
- Therapy commercialization: XenoTherapeutics is developing realSKIN and other regenerative medicine therapies for commercial launch. As a not-for-profit research organization, the company focuses on advancing therapies that improve quality of life rather than maximizing shareholder returns.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
XenoTherapeutics product offering
Product offeringCore offering
XenoTherapeutics develops and produces regenerative medicine products from genetically engineered pigs, with realSKIN—a living skin transplant for severe injuries and burns—as its first commercial-stage therapy. The company is building a xenotransplantation platform intended to replace donated human cadaver tissue with a consistent, living, scalable donor source across multiple tissue and organ applications.
Product overview
XenoTherapeutics is a not-for-profit biotechnology research foundation offering a platform-based approach to regenerative medicine. Its core product is realSKIN, a living skin transplant made from genetically engineered pigs, which serves as a scalable alternative to donated human cadaver tissue. The company is developing its platform to extend this breakthrough approach across a range of tissue and cell therapy applications beyond skin.
Differentiator
Problem solved
Functional benefit
Brands
- realSKIN: Living skin transplant therapy designed to support healing after severe injury, produced from genetically engineered pigs
Products and services
- realSKIN realSKIN is a living skin transplant derived from genetically engineered pigs, designed to support healing after severe injury and to replace donated human cadaver tissue in burn and wound care applications. It is targeted at patients with serious conditions requiring skin transplantation and is being developed and delivered through clinical partnerships with healthcare providers, hospitals, and burn centers.
Quantifiable outcome
- RMAT Designation for realSKIN validated by FDA
Companies that use XenoTherapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
XenoTherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
XenoTherapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Alexis BiocoreAlexis Bio and XenoTherapeutics are committed to developing advanced regenerative medicine therapies such as realSKIN for patients with serious conditions. The RMAT Designation of realSKIN speaks to the strength of the clinical data generated during prior clinical studies, and this partnership supports ongoing development and commercialization efforts.
- Academic InstitutionscoreXenoTherapeutics collaborates with investigators and academic institutions to explore new indications for realSKIN as well as other regenerative medicine therapies. These partnerships support clinical development, research expansion, and broader adoption of xenotransplantation-based treatments.
Scale indicators3 records
Recent moves5 records
Expansion highlights6 records
XenoTherapeutics competitors and assessment
Company assessmentDirect peers
- Avita Medical: Commercial regenerative medicine company selling RECELL, an autologous cell spray system for burn treatment. Competes with realSKIN in the burn care and skin regeneration market.
- eGenesis: Clinical-stage xenotransplantation company developing engineered pig organs and tissues for human transplant. Closely comparable to XenoTherapeutics in donor-source platform approach and target indications.
- Organogenesis: Commercial-stage regenerative medicine company selling skin and wound healing products (e.g., Apligraf). Direct competitor in the skin substitute and biologic wound care market that realSKIN targets.
- MiMedx: Regenerative medicine company focused on human placental tissue allografts for wound healing and surgical recovery. Competes in the same skin/wound regeneration end market with an alternative biologic approach.
- Vericel: Commercial-stage cell therapy company selling autologous skin substitutes (e.g., Epicel) for severe burns. Direct comparator in the living skin substitute market for burn and wound treatment.
Broad incumbents
- United Therapeutics: Public biotech with a dedicated xenotransplantation program (via Revivicor) developing pig-derived organs and tissues. Operates at much greater scale but competes for the same xenotransplant opportunity.
- Smith+Nephew: Global medical device company with a large advanced wound management portfolio including skin substitutes and biologic dressings. Represents established competition in the wound healing space.
- Integra LifeSciences: Diversified medical technology company with a regenerative tissue technologies segment (e.g., Integra Dermal Regeneration Template). Broad incumbent in wound and skin regeneration.
- Convatec: Global medical products company with a significant advanced wound care portfolio including skin substitute technologies. Adjacent incumbent competing for share in wound healing.
- Mallinckrodt (Stratatech): Through its Stratatech subsidiary, Mallinckrodt commercializes living skin substitutes (e.g., StrataGraft) for burn treatment. Directly comparable product category to realSKIN.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
XenoTherapeutics social profiles
Digital presenceXenoTherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
XenoTherapeutics leadership team
Management profileNumber of profiles
Profiles2 records
XenoTherapeutics subsidiaries and ownership
Company hierarchySubsidiaries3 records
XenoTherapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
XenoTherapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about XenoTherapeutics
What does XenoTherapeutics do?
XenoTherapeutics develops and produces regenerative medicine products from genetically engineered pigs, with realSKIN—a living skin transplant for severe injuries and burns—as its first commercial-stage therapy. The company is building a xenotransplantation platform intended to replace donated human cadaver tissue with a consistent, living, scalable donor source across multiple tissue and organ applications.
Is XenoTherapeutics a public or private company?
XenoTherapeutics is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was XenoTherapeutics founded?
XenoTherapeutics was founded in 2016. It employs 1 to 10 people.
Where is XenoTherapeutics based?
XenoTherapeutics is headquartered in Boston, United States, in the North America region.
How does XenoTherapeutics make money?
One revenue line is on record: therapy commercialization.
Who are XenoTherapeutics's main competitors?
Direct peers on record are Avita Medical, eGenesis, Organogenesis, MiMedx and Vericel. Broad incumbents are United Therapeutics, Smith+Nephew, Integra LifeSciences, Convatec and Mallinckrodt (Stratatech).
Does XenoTherapeutics have an API?
No public API is recorded for XenoTherapeutics.
What industry is XenoTherapeutics in?
XenoTherapeutics's product category is Regenerative Medicine / Xenotransplantation Therapies. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 2836.